NASEM report offers strategies to make prescription drugs more affordable

Nov 30, 2017 - 09:17 AM

Access to effective and affordable medicines is necessary for public health, social equity, and economic development, but the biopharmaceutical sector is not meeting that need, according to a report released today by the National Academies of Sciences, Engineering, and Medicine. “Our report seeks to address the market failures that currently permeate the biopharmaceutical sector, such as lack of competition due to distortions in the application of the patent protection process, the imbalance between the negotiating power of suppliers and purchasers, and the convoluted structure of the supply chain,” the authors note. The report offers eight recommendations with 27 actions to improve the affordability of prescription drugs without discouraging the development of new and more effective drugs for the future. Among other measures, the report recommends improving methods for assessing the value that drugs provide and ensuring that incentives to develop drugs for rare diseases are not extended to widely sold drugs; taking actions to continually foster greater access to off-patent generic drugs; and discouraging direct-to-consumer advertisements for prescription drugs. 

Related News Articles

Headline
CMS releases proposed rules on two drug pricing models
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
Administration reaches deals with 9 drug companies to lower drug costs
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
House passes narrow health care package; sets up a vote on EPTCs in January
The House Dec. 17 passed the Lower Health Care Premiums for All Americans Act (H.R. 6703), legislation to expand association health plans, increase…
Headline
AHA urges Elevance Health to rescind Anthem’s ‘Nonparticipating Provider Policy,’ citing harm to patient care access
The AHA Dec. 17 urged Elevance Health, which is the parent company of the Anthem brand of health plans, to rescind Anthem’s nonparticipating provider…
Headline
Blog: Putting 340B Program Growth in Context
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Headline
Report finds increasing concentration in commercial health, MA insurance markets 
The American Medical Association Dec. 16 released its latest annual report on health insurance competition, finding that 97% of commercial markets were highly…